Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss

被引：16
|
作者：
Tawbi, Hussein Abdul-Hassan
Peng, Weiyi
Milton, Denai
Amaria, Rodabe Navroze
Glitza, Isabella Claudia
Hwu, Wen-Jen
Patel, Sapna Pradyuman
Wong, Michael K. K.
Woodman, Scott Eric
Yee, Cassian
McQuade, Jennifer Leigh
Tetzlaff, Michael T.
Lazar, Alexander J.
Cain, Suzanne
Burton, Elizabeth M.
Beumer, Jan Hendrik
Hwu, Patrick
Davies, Michael A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NSABP Fdn, Pittsburgh, PA USA
[3] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS9596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9596
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
    Haymaker, C.
    Andtbacka, R. H. I.
    Johnson, D. B.
    Shaheen, M. F.
    Rahimian, S.
    Chunduru, S.
    Gabrail, N.
    Doolittle, G.
    Puzanov, I.
    Markowitz, J.
    Bernatchez, C.
    Diab, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S736 - S736
  • [22] Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
    Barrientos, Jacqueline Claudia
    Furman, Richard R.
    Leonard, John
    Flinn, Ian
    Rai, Kanti Roop
    De Vos, Sven
    Schreeder, Marshall T.
    Wagner-Johnston, Nina D.
    Sharman, Jeff Porter
    Boyd, Thomas E.
    Fowler, Nathan Hale
    Holes, Leanne
    Johnson, David Michael
    Li, Daniel
    Dansey, Roger D.
    Jahn, Thomas Michael
    Coutre, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Grégoire Marret
    Nicolas Isambert
    Keyvan Rezai
    Jocelyn Gal
    Esma Saada-Bouzid
    Frédéric Rolland
    Maggy Chausson
    Edith Borcoman
    Marie Alt
    Jerzy Klijanienko
    Damien Vansteene
    Joël Guigay
    Maud Kamal
    Ivan Bièche
    Christophe Le Tourneau
    Investigational New Drugs, 2021, 39 : 1641 - 1648
  • [24] Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Marret, Gregoire
    Isambert, Nicolas
    Rezai, Keyvan
    Gal, Jocelyn
    Saada-Bouzid, Esma
    Rolland, Frederic
    Chausson, Maggy
    Borcoman, Edith
    Alt, Marie
    Klijanienko, Jerzy
    Vansteene, Damien
    Guigay, Joel
    Kamal, Maud
    Bieche, Ivan
    Le Tourneau, Christophe
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1641 - 1648
  • [25] Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
    Blagden, S.
    Elshani, M.
    Symeonides, S. N.
    Skolariki, A.
    Haris, N. R.
    Boh, Z. Y.
    Dickson, A.
    Um, I. H.
    Zhang, Y.
    McKissock, F. G.
    Oelmann, E.
    Bloss, J.
    Cook, N.
    Evans, T. R. J.
    Plummer, R.
    Harrison, D. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S523 - S524
  • [26] Phase I study of PI3Kα inhibitor BYL719+aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Shah, Payal D.
    Moynahan, Mary E.
    Modi, Shanu
    Hamilton, Nicola
    Caravella, Betty Ann
    Zamora, Stephen
    Dang, Chau
    Gilewski, Theresa
    Traina, Tiffany
    Comen, Elizabeth
    Sugarman, Steven M.
    D'Andrea, Gabriella
    Lake, Diana
    Goldfarb, Shari
    Patil, Sujata
    Covey, Anne
    Berger, Michael
    Lacouture, Mario
    Norton, Larry
    Hudis, Clifford A.
    BaseIga, Jose
    Chandarlapaty, Sarat
    Dickler, Maura
    CANCER RESEARCH, 2015, 75
  • [27] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    Grilley-Olson, J. E.
    Bedard, P. L.
    Fasolo, A.
    Cornfeld, M.
    Cartee, L.
    Razak, A. R. Abdul
    Stayner, L. -A.
    Wu, Y.
    Greenwood, R.
    Singh, R.
    Lee, C. B.
    Bendell, J.
    Burris, H. A.
    Del Conte, G.
    Sessa, C.
    Infante, J. R.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 740 - 749
  • [28] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    J. E. Grilley-Olson
    P. L. Bedard
    A. Fasolo
    M. Cornfeld
    L. Cartee
    A. R. Abdul Razak
    L.-A. Stayner
    Y. Wu
    R. Greenwood
    R. Singh
    C. B. Lee
    J. Bendell
    H. A. Burris
    G. Del Conte
    C. Sessa
    J. R. Infante
    Investigational New Drugs, 2016, 34 : 740 - 749
  • [29] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors
    Burris, H.
    Rodon, J.
    Sharma, S.
    Herbst, R. S.
    Tabernero, J.
    Infante, J. R.
    Silva, A.
    Demanse, D.
    Hackl, W.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer
    Brisson, Ryan J.
    Kochanny, Sara
    Arshad, Saba
    Dekker, Allison
    DeSouza, Jonas A.
    Saloura, Vassiliki
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (11): : 3842 - 3849
12345